Saprochaete clavata Chorioretinitis in a Post-chemotherapy Immunocompromised 9-Year-Old Child

Ocul Immunol Inflamm. 2023 Jul;31(5):1081-1084. doi: 10.1080/09273948.2022.2070502. Epub 2022 May 19.

Abstract

Purpose: To describe the management of bilateral chorioretinitis with Saprochaete clavata in a post-chemotherapy immunocompromised young patient.

Method: A retrospective case report.

Result: A 9-year-old boy treated with chemotherapy for type 2 acute myeloid leukaemia was diagnosed with Saprochaete clavata (formerly called Geotrichum clavatum) fungaemia. Systematic ocular examination revealed chorioretinitis of the left eye becoming bilateral within the next 3 days. Therapy was based on systemic administration of voriconazole, amphotericin B and flucytosine associated with granulocytic stimulation without stabilizing the ophthalmological situation. Bilateral intravitreal injections of amphotericin B were administered. Voriconazole residual blood concentration was monitored to adjust daily dose. Final best corrected visual acuity in the right eye was 20/50 and 20/20 in the left eye.

Conclusion: This is the first report of chorioretinitis with Saprochaete clavata. Because of its unpredictable pharmacokinetics, especially in pediatric population, therapeutic drug monitoring of voriconazole is essential to control fungal infection.

Keywords: Chorioretinitis; Geotrichum clavatum; Saprochaete clavate; fungaemia; uveitis; voriconazole.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents* / therapeutic use
  • Child
  • Chorioretinitis* / diagnosis
  • Chorioretinitis* / drug therapy
  • Chorioretinitis* / microbiology
  • Humans
  • Male
  • Retrospective Studies
  • Voriconazole / therapeutic use

Substances

  • Voriconazole
  • Antifungal Agents
  • Amphotericin B

Supplementary concepts

  • Magnusiomyces clavatus